{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:01:10Z","timestamp":1774627270954,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T00:00:00Z","timestamp":1491350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T00:00:00Z","timestamp":1491350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Degradation of the biologically potent octapeptide angiotensin Ang II-(1-8) is mediated by the activities of several peptidases. The conversion of Ang II to the septapeptide Ang-(1-7) is of particular interest as the latter also confers organ protection. The conversion is catalyzed by angiotensin-converting enzyme 2 and other enzymes that selectively cleave the peptide bond between the proline and the phenylalanine at the carboxyl terminus of Ang II. The contribution of various enzyme activities that collectively lead to the formation of Ang-(1-7) from Ang II, in both normal conditions and in disease states, remains only partially understood. This is largely due to the lack of a reliable and sensitive method to detect these converting activities in complex samples, such as blood and tissues. Here, we report a fluorometric method to measure carboxypeptidase activities that cleave the proline-phenylalanine dipeptide bond in Ang II. This method is also suitable for measuring the conversion of apelin-13. The assay detects the release of phenylalanine amino acid in a reaction with the yeast enzyme of phenylalanine ammonia lyase (PAL). When used in cell and mouse organs, the assay can robustly measure endogenous Ang II and apelin-13-converting activities involved in the renin-angiotensin and the apelinergic systems, respectively.<\/jats:p>","DOI":"10.1038\/srep45473","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T12:31:46Z","timestamp":1491395506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A Fluorometric Method of Measuring Carboxypeptidase Activities for Angiotensin II and Apelin-13"],"prefix":"10.1038","volume":"7","author":[{"given":"Pan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Wysocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Serfozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomokazu","family":"Souma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Batlle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,5]]},"reference":[{"key":"BFsrep45473_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2012.249","volume":"9","author":"B Seva Pessoa","year":"2013","unstructured":"Seva Pessoa, B. et al. Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol 9, 26\u201336, doi: 10.1038\/nrneph.2012.249 (2013).","journal-title":"Nat Rev Nephrol"},{"key":"BFsrep45473_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","volume":"50","author":"M Bader","year":"2010","unstructured":"Bader, M. Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy. Annual Review of Pharmacology and Toxicology 50, 439\u2013465, doi: 10.1146\/annurev.pharmtox.010909.105610 (2010).","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"BFsrep45473_CR3","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.2174\/1381612811319170009","volume":"19","author":"K Hiroyuki","year":"2013","unstructured":"Hiroyuki, K., Hirohito, M., Tsutomu, M. & Akira, N. Angiotensin II Blockade and Renal Protection. Current Pharmaceutical Design 19, 3033\u20133042, doi: 10.2174\/1381612811319170009 (2013).","journal-title":"Current Pharmaceutical Design"},{"key":"BFsrep45473_CR4","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/clinchem\/37.8.1390","volume":"37","author":"TP Gorski","year":"1991","unstructured":"Gorski, T. P. & Campbell, D. J. Angiotensin-converting enzyme determination in plasma during therapy with converting enzyme inhibitor: two methods compared. Clinical Chemistry 37, 1390\u20131393 (1991).","journal-title":"Clinical Chemistry"},{"key":"BFsrep45473_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/ajcp\/66.2.416","volume":"66","author":"J Friedland","year":"1976","unstructured":"Friedland, J. & Silverstein, E. A Sensitive Fluorimetric Assay for Serum Angiotensin-con venrting Enzyme. American Journal of Clinical Pathology 66, 416\u2013424, doi: 10.1093\/ajcp\/66.2.416 (1976).","journal-title":"American Journal of Clinical Pathology"},{"key":"BFsrep45473_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0954-6111(08)80054-6","volume":"84","author":"M Matucci-Cerinic","year":"1990","unstructured":"Matucci-Cerinic, M. et al. Clinical correlations of plasma angiotensin converting enzyme (ACE) activity in systemic sclerosis: a longitudinal study of plasma ACE level, endothelial injury and lung involvement. Respiratory Medicine 84, 283\u2013287, doi: 10.1016\/S0954-6111(08)80054-6 (1990).","journal-title":"Respiratory Medicine"},{"key":"BFsrep45473_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0272-5231(05)70421-4","volume":"18","author":"U Costabel","year":"1997","unstructured":"Costabel, U. & Teschler, H. Biochemical changes in sarcoidosis. Clin Chest Med 18, 827\u2013842 (1997).","journal-title":"Clin Chest Med"},{"key":"BFsrep45473_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1515\/CCLM.2002.042","volume":"40","author":"B Baudin","year":"2002","unstructured":"Baudin, B. New aspects on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med 40, 256\u2013265, doi: 10.1515\/CCLM.2002.042 (2002).","journal-title":"Clin Chem Lab Med"},{"key":"BFsrep45473_CR9","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1021\/pr100564r","volume":"9","author":"SM Danilov","year":"2010","unstructured":"Danilov, S. M. et al. Conformational Fingerprinting of the Angiotensin I-Converting Enzyme (ACE). 1. Application in Sarcoidosis. Journal of Proteome Research 9, 5782\u20135793, doi: 10.1021\/pr100564r (2010).","journal-title":"Journal of Proteome Research"},{"key":"BFsrep45473_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1161\/hypertensionaha.115.05093","volume":"66","author":"J Wysocki","year":"2015","unstructured":"Wysocki, J., Wilsbacher, L. & Batlle, D. Angiotensins and the Heart. Is Angiotensin-(1-7) Cardioprotective? Hypertension 66, 260\u2013262, doi: 10.1161\/hypertensionaha.115.05093 (2015).","journal-title":"Hypertension"},{"key":"BFsrep45473_CR11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/01.hyp.19.6.692","volume":"19","author":"K Yamamoto","year":"1992","unstructured":"Yamamoto, K., Chappell, M. C., Brosnihan, K. B. & Ferrario, C. M. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19, 692\u2013696, doi: 10.1161\/01.hyp.19.6.692 (1992).","journal-title":"Hypertension"},{"key":"BFsrep45473_CR12","doi-asserted-by":"publisher","first-page":"H137","DOI":"10.1152\/ajpheart.00618.2015","volume":"310","author":"MC Chappell","year":"2016","unstructured":"Chappell, M. C. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? American Journal of Physiology - Heart and Circulatory Physiology 310, H137\u2013H152, doi: 10.1152\/ajpheart.00618.2015 (2016).","journal-title":"American Journal of Physiology - Heart and Circulatory Physiology"},{"key":"BFsrep45473_CR13","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario, C. M. et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation 111, 2605 (2005).","journal-title":"Circulation"},{"key":"BFsrep45473_CR14","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.2337\/db06-0033","volume":"55","author":"J Wysocki","year":"2006","unstructured":"Wysocki, J. et al. ACE and ACE2 activity in diabetic mice. Diabetes 55, 2132\u20132139, doi: 10.2337\/db06-0033 (2006).","journal-title":"Diabetes"},{"key":"BFsrep45473_CR15","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1161\/01.hyp.0000215588.38536.30","volume":"47","author":"KM Elased","year":"2006","unstructured":"Elased, K. M., Cunha, T. S., Gurley, S. B., Coffman, T. M. & Morris, M. New Mass Spectrometric Assay for Angiotensin-Converting Enzyme 2 Activity. Hypertension 47, 1010\u20131017, doi: 10.1161\/01.hyp.0000215588.38536.30 (2006).","journal-title":"Hypertension"},{"key":"BFsrep45473_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/ajh.2010.51","volume":"23","author":"AJ Trask","year":"2010","unstructured":"Trask, A. J. et al. Inhibition of Angiotensin-Converting Enzyme 2 Exacerbates Cardiac Hypertrophy and Fibrosis in Ren-2 Hypertensive Rats. American Journal of Hypertension 23, 687\u2013693, doi: 10.1038\/ajh.2010.51 (2010).","journal-title":"American Journal of Hypertension"},{"key":"BFsrep45473_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11906-014-0420-5","volume":"16","author":"J Varagic","year":"2014","unstructured":"Varagic, J., Ahmad, S., Nagata, S. & Ferrario, C. M. ACE2: Angiotensin II\/Angiotensin-(1-7) Balance in Cardiac and Renal Injury. Current Hypertension Reports 16, 1\u20139, doi: 10.1007\/s11906-014-0420-5 (2014).","journal-title":"Current Hypertension Reports"},{"key":"BFsrep45473_CR18","doi-asserted-by":"publisher","first-page":"H736","DOI":"10.1152\/ajpheart.00937.2006","volume":"292","author":"JL Grobe","year":"2007","unstructured":"Grobe, J. L. et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). American Journal of Physiology - Heart and Circulatory Physiology 292, H736\u2013H742, doi: 10.1152\/ajpheart.00937.2006 (2007).","journal-title":"American Journal of Physiology - Heart and Circulatory Physiology"},{"key":"BFsrep45473_CR19","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/joe-12-0341","volume":"216","author":"RAS Santos","year":"2013","unstructured":"Santos, R. A. S., Ferreira, A. J., Verano-Braga, T. & Bader, M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin\u2013angiotensin system. Journal of Endocrinology 216, R1\u2013R17, doi: 10.1530\/joe-12-0341 (2013).","journal-title":"Journal of Endocrinology"},{"key":"BFsrep45473_CR20","doi-asserted-by":"publisher","first-page":"17962","DOI":"10.1074\/jbc.M106101200","volume":"277","author":"Z Shariat-Madar","year":"2002","unstructured":"Shariat-Madar, Z., Mahdi, F. & Schmaier, A. H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277, 17962\u201317969, doi: 10.1074\/jbc.M106101200 (2002).","journal-title":"J Biol Chem"},{"key":"BFsrep45473_CR21","doi-asserted-by":"crossref","unstructured":"Maier, C. et al. Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II. Journal of Molecular Medicine, 1\u201314, doi: 10.1007\/s00109-017-1513-9 (2017).","DOI":"10.1007\/s00109-017-1513-9"},{"key":"BFsrep45473_CR22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/0024-3205(93)90108-F","volume":"52","author":"WR Welches","year":"1993","unstructured":"Welches, W. R., Bridget Brosnihan, K. & Ferrario, C. M. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: Angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sciences 52, 1461\u20131480, doi: 10.1016\/0024-3205(93)90108-F (1993).","journal-title":"Life Sciences"},{"key":"BFsrep45473_CR23","first-page":"699A","volume":"26","author":"PD Serfozo","year":"2015","unstructured":"Serfozo P. D., W. J., Ye, M. & Batlle, D. Massive formation of ang(1-7) from angII(1-8) is largely ace2 independent [Abstract]. J Am Soc Nephrol. 26, 699A\u2013700A (2015).","journal-title":"J Am Soc Nephrol"},{"key":"BFsrep45473_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1161\/01.hyp.32.3.496","volume":"32","author":"K Yamada","year":"1998","unstructured":"Yamada, K., Iyer, S. N., Chappell, M. C., Ganten, D. & Ferrario, C. M. Converting Enzyme Determines Plasma Clearance of Angiotensin-(1-7). Hypertension 32, 496\u2013502, doi: 10.1161\/01.hyp.32.3.496 (1998).","journal-title":"Hypertension"},{"key":"BFsrep45473_CR25","doi-asserted-by":"crossref","unstructured":"Chappell, M., Marshall, A., Alzayadneh, E., Shaltout, H. & Diz, D. Update on the Angiotensin Converting Enzyme 2-Angiotensin (1-7)-Mas Receptor Axis: Fetal Programing, Sex Differences, and Intracellular Pathways. Frontiers in Endocrinology 4, doi: 10.3389\/fendo.2013.00201 (2014).","DOI":"10.3389\/fendo.2013.00201"},{"key":"BFsrep45473_CR26","doi-asserted-by":"publisher","first-page":"E1016","DOI":"10.1152\/ajpendo.00515.2011","volume":"302","author":"N Grobe","year":"2012","unstructured":"Grobe, N., Elased, K. M., Cool, D. R. & Morris, M. Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. American Journal of Physiology - Endocrinology And Metabolism 302, E1016 (2012).","journal-title":"American Journal of Physiology - Endocrinology And Metabolism"},{"key":"BFsrep45473_CR27","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/ndt\/gfl632","volume":"22","author":"S Keidar","year":"2007","unstructured":"Keidar, S., Strizevsky, A., Raz, A. & Gamliel-Lazarovich, A. ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. Nephrology Dialysis Transplantation 22, 597\u2013601, doi: 10.1093\/ndt\/gfl632 (2007).","journal-title":"Nephrology Dialysis Transplantation"},{"key":"BFsrep45473_CR28","doi-asserted-by":"publisher","first-page":"R1953","DOI":"10.1152\/ajpregu.90592.2008","volume":"295","author":"A Levy","year":"2008","unstructured":"Levy, A. et al. ACE2 expression and activity are enhanced during pregnancy. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology 295, R1953\u2013R1961, doi: 10.1152\/ajpregu.90592.2008 (2008).","journal-title":"American Journal of Physiology - Regulatory, Integrative and Comparative Physiology"},{"key":"BFsrep45473_CR29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/mnh.0000000000000241","volume":"25","author":"LM Yamaleyeva","year":"2016","unstructured":"Yamaleyeva, L. M., Shaltout, H. A. & Varagic, J. Apelin-13 in blood pressure regulation and cardiovascular disease. Current Opinion in Nephrology and Hypertension 25, 396\u2013403, doi: 10.1097\/mnh.0000000000000241 (2016).","journal-title":"Current Opinion in Nephrology and Hypertension"},{"key":"BFsrep45473_CR30","first-page":"273","volume":"11","author":"AZ Kalea","year":"2010","unstructured":"Kalea, A. Z. & Batlle, D. Apelin and ACE2 in cardiovascular disease. Curr Opin Investig Drugs 11, 273\u2013282 (2010).","journal-title":"Curr Opin Investig Drugs"},{"key":"BFsrep45473_CR31","doi-asserted-by":"publisher","first-page":"14838","DOI":"10.1074\/jbc.M200581200","volume":"277","author":"C Vickers","year":"2002","unstructured":"Vickers, C. et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277, 14838\u201314843, doi: 10.1074\/jbc.M200581200 (2002).","journal-title":"J Biol Chem"},{"key":"BFsrep45473_CR32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1050-1738(02)00233-5","volume":"13","author":"GY Oudit","year":"2003","unstructured":"Oudit, G. Y., Crackower, M. A., Backx, P. H. & Penninger, J. M. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 13, 93\u2013101 (2003).","journal-title":"Trends Cardiovasc Med"},{"key":"BFsrep45473_CR33","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1161\/HYPERTENSIONAHA.112.198622","volume":"60","author":"M Ye","year":"2012","unstructured":"Ye, M. et al. Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension 60, 730\u2013740, doi: 10.1161\/HYPERTENSIONAHA.112.198622 (2012).","journal-title":"Hypertension"},{"key":"BFsrep45473_CR34","doi-asserted-by":"crossref","unstructured":"Carrera, E., Linares, A., Joachim, A., Jean-Baptiste, M. & Speth, R. MCA-APK(Dnp) is not a selective substrate of angiotensin-converting enzyme-2 (1067.6). The FASEB Journal 28 (2014).","DOI":"10.1096\/fasebj.28.1_supplement.1067.6"},{"key":"BFsrep45473_CR35","doi-asserted-by":"publisher","first-page":"30113","DOI":"10.1074\/jbc.M505111200","volume":"280","author":"DW Lambert","year":"2005","unstructured":"Lambert, D. W. et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280, 30113\u201330119, doi: 10.1074\/jbc.M505111200 (2005).","journal-title":"J Biol Chem"},{"key":"BFsrep45473_CR36","doi-asserted-by":"publisher","first-page":"F600","DOI":"10.1152\/ajprenal.00600.2012","volume":"305","author":"J Wysocki","year":"2013","unstructured":"Wysocki, J. et al. Regulation of urinary ACE2 in diabetic mice. American Journal of Physiology - Renal Physiology 305, F600\u2013F611, doi: 10.1152\/ajprenal.00600.2012 (2013).","journal-title":"American Journal of Physiology - Renal Physiology"},{"key":"BFsrep45473_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1113\/expphysiol.2007.040352","volume":"93","author":"RA Lew","year":"2008","unstructured":"Lew, R. A. et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Experimental Physiology 93, 685\u2013693, doi: 10.1113\/expphysiol.2007.040352 (2008).","journal-title":"Experimental Physiology"},{"key":"BFsrep45473_CR38","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1016\/j.peptides.2005.01.009","volume":"26","author":"F Gembardt","year":"2005","unstructured":"Gembardt, F. et al. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 26, 1270\u20131277, doi: 10.1016\/j.peptides.2005.01.009 (2005).","journal-title":"Peptides"},{"key":"BFsrep45473_CR39","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1113\/expphysiol.2007.040246","volume":"93","author":"PJ Garabelli","year":"2008","unstructured":"Garabelli, P. J., Modrall, J. G., Penninger, J. M., Ferrario, C. M. & Chappell, M. C. Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Experimental Physiology 93, 613\u2013621, doi: 10.1113\/expphysiol.2007.040246 (2008).","journal-title":"Experimental Physiology"},{"key":"BFsrep45473_CR40","doi-asserted-by":"publisher","first-page":"8258","DOI":"10.1073\/pnas.1432869100","volume":"100","author":"RAS Santos","year":"2003","unstructured":"Santos, R. A. S. et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proceedings of the National Academy of Sciences 100, 8258\u20138263, doi: 10.1073\/pnas.1432869100 (2003).","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"BFsrep45473_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MNH.0b013e3283406f57","volume":"20","author":"CM Ferrario","year":"2011","unstructured":"Ferrario, C. M. ACE2: more of Ang-(1-7) or less Ang II? Current Opinion in Nephrology and Hypertension 20, 1\u20136, doi: 10.1097\/MNH.0b013e3283406f57 (2011).","journal-title":"Current Opinion in Nephrology and Hypertension"},{"key":"BFsrep45473_CR42","doi-asserted-by":"publisher","first-page":"H3019","DOI":"10.1152\/ajpheart.01198.2006","volume":"292","author":"AJ Trask","year":"2007","unstructured":"Trask, A. J., Averill, D. B., Ganten, D., Chappell, M. C. & Ferrario, C. M. Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. American Journal of Physiology - Heart and Circulatory Physiology 292, H3019\u2013H3024, doi: 10.1152\/ajpheart.01198.2006 (2007).","journal-title":"American Journal of Physiology - Heart and Circulatory Physiology"},{"key":"BFsrep45473_CR43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1161\/hypertensionaha.109.141622","volume":"55","author":"TM Gwathmey","year":"2010","unstructured":"Gwathmey, T. M. et al. Angiotensin-(1-7)-Angiotensin-Converting Enzyme 2 Attenuates Reactive Oxygen Species Formation to Angiotensin II Within the Cell Nucleus. Hypertension 55, 166\u2013171, doi: 10.1161\/hypertensionaha.109.141622 (2010).","journal-title":"Hypertension"},{"key":"BFsrep45473_CR44","doi-asserted-by":"publisher","first-page":"C939","DOI":"10.1152\/ajpcell.00081.2013","volume":"304","author":"JC Velez","year":"2013","unstructured":"Velez, J. C. Prolyl carboxypeptidase: a forgotten kidney angiotensinase. Focus on \u201cIdentification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry\u201d. Am J Physiol Cell Physiol 304, C939\u2013940, doi: 10.1152\/ajpcell.00081.2013 (2013).","journal-title":"Am J Physiol Cell Physiol"},{"key":"BFsrep45473_CR45","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1021\/jm901104g","volume":"53","author":"J Lawandi","year":"2010","unstructured":"Lawandi, J., Gerber-Lemaire, S., Juillerat-Jeanneret, L. & Moitessier, N. Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem 53, 3423\u20133438, doi: 10.1021\/jm901104g (2010).","journal-title":"J Med Chem"},{"key":"BFsrep45473_CR46","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/00004872-199107000-00008","volume":"9","author":"WR Welches","year":"1991","unstructured":"Welches, W. R. et al. Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. J Hypertens 9, 631\u2013638 (1991).","journal-title":"J Hypertens"},{"key":"BFsrep45473_CR47","doi-asserted-by":"publisher","first-page":"C945","DOI":"10.1152\/ajpcell.00346.2012","volume":"304","author":"N Grobe","year":"2013","unstructured":"Grobe, N. et al. Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. American Journal of Physiology - Cell Physiology 304, C945\u2013C953, doi: 10.1152\/ajpcell.00346.2012 (2013).","journal-title":"American Journal of Physiology - Cell Physiology"},{"key":"BFsrep45473_CR48","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/hypertensionaha.109.138420","volume":"55","author":"J Wysocki","year":"2010","unstructured":"Wysocki, J. et al. Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2: Prevention of Angiotensin II\u2013Dependent Hypertension. Hypertension 55, 90\u201398, doi: 10.1161\/hypertensionaha.109.138420 (2010).","journal-title":"Hypertension"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep45473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep45473","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/srep45473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/srep45473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T23:47:24Z","timestamp":1671839244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep45473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,5]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,6,19]]}},"alternative-id":["BFsrep45473"],"URL":"https:\/\/doi.org\/10.1038\/srep45473","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,5]]},"assertion":[{"value":"10 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45473"}}